GPRO Continues To Enjoy An Enviable Advantage Amongst New U.S. HPV Entrants, Piper Jaffray Reports

Piper Jaffray continues to believe that Gen-Probe Inc. GPRO enjoys an enviable advantage amongst the new U.S. HPV entrants “with their large installed base of Tigris' that will aid initial account conversions (and believe we have modeled said share shift accordingly).” “That said, we suspect Qiagen will make the most of the mathematically lower (but still statistically equivalent) Aptima sensitivity,” Piper Jaffray writes. Gen-Probe closed Friday at $81.84.